ClinicalTrials.gg
CompletedNCT03526978Updated Jan 25, 2019

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

A Phase 3 interventional study of Investigational sIPV and Control IPV in Poliomyelitis, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 60 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-25.

Sponsored by Sinovac Biotech Co., Ltd · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
60 Days to 90 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd — 2 open to participants now, 3 under way, none of them phase 3. Poliomyelitis · Sinovac Biotech Co., Ltd.

Enrollment
5th of 13
1,200 · median 708
Started
2017
the only one that year
Phase 3
6 of 15
none open now
Registered
2nd of 15
by date

Among the 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2017, is one of 6 in phase 3, and was the 2nd registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

2 of the 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 60 Days to 90 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.

Read the detailed description

The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants. The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company. 1200 healthy infants between 60-90 days will be randomly assigned into experimental group or control group in the ratio 1:1.

03

Conditions studied

  • Poliomyelitis

Browse trials for

Keywords

  • Sabin strain
  • Inactivated poliovirus vaccine
  • poliomyelitis
  • safety
  • immunogenicity
  • infant
04

Who can participate

Ages eligible
60 Days to 90 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer between 60-90 days old;
  • Healthy volunteers who fulfill all the required conditions for receiving the vaccine as established by medical history and clinical examination and determined by investigators;
  • Proven legal identity;
  • Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment;
  • Complying with the requirement of the study protocol;

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination with Poliovirus Vaccine;
  • History of allergy to any vaccine, or any ingredient of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
  • Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
  • disease or immunodeficiency/;
  • Severe nervous system disease (epilepsy, seizures or convulsions) or mental illness;
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or abnormalities) , or obvious bruising or coagulation disorders;
  • Any immunosuppressant, cytotoxic medicine, or inhaled (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) prior to study entry;
  • Blood product prior to study entry;
  • Any other medicine(s) within 30 days prior to study entry;
  • Any within 14 days prior to study entry;
  • Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Axillary temperature > 37.0 °C;
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,200 participants (actual)

Study arms

  • Experimental
    Experimental Group

    The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd. Intervention: investigational sIPV

    Biological: Investigational sIPV

  • Active comparator
    Control Group

    The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV

    Biological: Control IPV

Interventions

  • BiologicalInvestigational sIPV

    Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV

  • BiologicalControl IPV

    Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV

06

What researchers measure

Primary outcomes

  1. The seroconversion rates (SCRs) of each group after primary immunization.

    Subjects whose pre-immune antibody level \< 1:8 and post-immune antibody level ≥ 1:8, or those whose pre-immune antibody level ≥ 1:8 and the increase of post-immune antibody level ≥ 4 folds are considered seroconverted. Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).

    Time frame: 90 days

Secondary outcomes

  1. The incidences of solicited adverse events (AEs) of each group.

    Solicited AEs occurred within 7 days after each injection will be collected.

    Time frame: 7 days

  2. The incidences of unsolicited adverse events (AEs) of each group.

    Unsolicited AEs occurred within 30 days after each injection will be collected.

    Time frame: 30 days

  3. The incidence of serious adverse events (SAEs) during the period of safety monitoring of each group.

    SAEs during the period of safety monitoring will be collected.

    Time frame: 90-420 days.

  4. The post-immune antibody positive rate of each group after primary immunization.

    Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).

    Time frame: 90 days

  5. The post-immune geometric mean titer (GMT) of each group after primary immunization.

    GMT of each group after primary immunization which lasts 60 days.

    Time frame: 90 days.

  6. The geometric mean fold increase (GMI) of each group after primary immunization.

    The GMI is the increase of post-immune GMT from pre-immune GMT.

    Time frame: 90 days

  7. The percentage of subjects with antibody ≥ 1:64 of each group after primary immunization.

    Percentage of subjects with antibody ≥ 1:64 of each group after three-dose

    Time frame: 90 days

  8. The antibody positive rate of each group before booster dose.

    Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. A booster dose at the age of 18months.

    Time frame: 420 days

  9. The geometric mean titer (GMT) of each group before booster dose.

    GMT of each group before booster dose which occurred at the age of 18months.

    Time frame: 420 days.

  10. The geometric mean fold increase (GMI) of each group before booster dose.

    The GMI is the increase of post-immune GMT from pre-i mmune GMT.

    Time frame: 420 days

  11. The percentage of subjects with antibody ≥ 1:64 of each group before booster dose.

    Percentage of subjects with antibody ≥ 1:64 of each group before booster dose which occurred at the age of 18months.

    Time frame: 420 days

  12. The post-immune antibody positive rate of each group after booster dose.

    Subjects whose post-immune antibody level ≥ 1:8 are co nsidered antibody positive

    Time frame: 570 days

  13. The post-immune geometric mean titer (GMT) of each group after booster dose.

    GMT of each group after booster dose. The booster dose at the age of 18months

    Time frame: 570 days

  14. The geometric mean fold increase (GMI) of each group after booster dose.

    The GMI is the increase of post-immune GMT from pre-immune GMT.

    Time frame: 570 days

  15. The percentage of subjecs with antibody ≥ 1:64 of each group after booster dose.

    Percentage of subjecs with antibody ≥ 1:64 of each group after booster dose which occurred at the age of 18months.

    Time frame: 570 days

07

Study locations

1 site
  • Pizhou County Center for Disease Control and Prevention
    Pizhou, Jiangsu 221300, China
08

References and documents

Publications

  • Hu Y, Wang J, Zeng G, Chu K, Jiang D, Zhu F, Ying Z, Chen L, Li C, Zhu F, Yin W. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial. J Infect Dis. 2019 Oct 8;220(10):1551-1557. doi: 10.1093/infdis/jiy736. PubMed 30958543 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Oct 2017, 2 months.

Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 2 months is below that.

Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2018
First posted
May 16, 2018
StartActual
Aug 8, 2017
Primary completionActual
Oct 18, 2017
CompletionActual
Apr 18, 2018
Last update
Jan 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03526978
Responsible party
Sponsor
First posted
May 16, 2018
Start date
Aug 8, 2017
Primary completion
Oct 18, 2017
Completion
Apr 18, 2018
Last update
Jan 25, 2019

Study contacts

Yuemei Hu
principal investigator · Jiangsu Provincial Center for Disease Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion